Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoVPN3008: Efficacy of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
NCT05168813Phase 3Completed
- Sponsor
- COVID-19 Prevention Network
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised trial of elasomeran and elasomeran + davesomeran in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by COVID-19 Prevention Network. Primary endpoints: First Occurrence of CDC-defined COVID-19 at Month 18, First Occurrence of COVE-defined COVID-19 at Month 18 and 5 more. Started Dec 2021; status: completed.
02
Drugs
elasomeranelasomeran + davesomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05168813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168813.